GL1X · GenesisL1 explorer

Research workbench

Crystal structure of human KRAS G12C covalently bound to a phthalazine inhibitor

Analyse Crystal structure of human KRAS G12C covalently bound to a phthalazine inhibitor in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
6PGO
Type
protein
Length
312 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
GTPase KRAS
UniProt
P01116
Ligands
GDP, OJ1, MG
Pockets
3 · best druggability 0.56

Structure

x-ray diffraction · 2 distinct chains · 38% helix, 26% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AGTPase KRASprotein16036% helix, 26% strandP01116
BGTPase KRASprotein15239% helix, 26% strandP01116

Ligands and binding sites

  • GDP · Guanosine-5'-diphosphate · ligand · 2 copies · chains A, B
  • OJ1 · 1-{4-[7-chloro-6-(2-fluoro-6-hydroxyphenyl)-4-phenylphthalazin-1-yl]piperazin-1-yl}propan-1-one · ligand · 2 copies · chains A, B
  • MG · Magnesium ion · metal · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
12630.560.7738MG, GDP, OJ1
22160.550.7932empty
3610.340.7716empty

Interfaces

1 interface between chains.

  • A–B · 580 Ų buried · 15 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 2 covalent (covalent ligand).

Compared structures

  • 6PGO · Crystal structure of human KRAS G12C covalently bound to a phthalazine inhibitor · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.